一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，肉瘤领域Poster Session中国共入选13项研究。期待中国专家在ASCO年会上展现风采！

肉瘤

Sarcoma

摘要号: 11525

标题：Two schedules of vincristine, irinotecan and temozolomide (VIT) for patients with relapsed or refractory Ewing sarcoma: A randomized controlled phase 2 trial.

报告人: 许婕

单位：北京大学人民医院

摘要号: 11526

标题：Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate as neoadjuvant therapy for osteosarcoma: A single-arm, exploratory phase II trial.

报告人：唐清连

单位：中山大学肿瘤防治中心

摘要号: 11530

标题：ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, for metastatic or unresectable osteosarcoma after standard chemotherapy: A multicenter, open-label, single-arm, phase 1 study.

报告人：沈靖南

单位：中山大学附属第一医院

摘要号: 11538

标题：Combination targeted therapy with avapritinib and sunitinib in patients with refractory gastrointestinal stromal tumors after failure of standard treatments: A small prospective pilot study.

报告人：Yanzhe Xia

单位：中山大学附属第一医院

摘要号: 11540

标题：Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)–resistant succinate dehydrogenase (SDH)–deficient gastrointestinal stromal tumor (GIST).

报告人：邱海波

单位：中山大学肿瘤防治中心

摘要号:11543

标题：Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors (GIST) as ≥4th line therapy: Long-term update from a single-arm, phase 2 trial.

报告人：李健

单位：北京大学肿瘤医院

摘要号: 11551

标题：Aristolochic acid (AA) exposure and telomere maintenance mechanism in liver angiosarcoma (AS).

报告人：Tom Wei-Wu Chen

单位：国立台湾大学医院

摘要号: 11553

标题：Efficacy and safety of anlotinib combined with anthracycline and ifosfamide followed by anlotinib maintenance in advanced soft tissue sarcoma: A single-arm, phase 2 trial.

报告人：刘增军

单位：山东第一医科大学附属肿瘤医院

摘要号: 11559

标题：Efficacy and safety profile of pimicotinib (ABSK021) in tenosynovial giant cell tumor (TGCT): Phase 1b update.

报告人：Lu Yao

单位：北京积水潭医院

摘要号: 11562

标题：HH2853, an EZH1/2 inhibitor, in patients with epithelioid sarcoma: Preliminary results from the phase 1 part of a first-in-human phase I/II study.

报告人：Qiuying Ma

单位：海河生物制药有限公司

摘要号: 11566

标题：A phase II clinical trial of chidamide in combination with toripalimab in patients with advanced soft tissue sarcoma.

报告人：张星

单位：中山大学肿瘤防治中心

摘要号: 11569

标题：Phase I/II study to evaluate penpulimab combined with anlotinib and epirubicin in the first-line treatment of soft tissue sarcoma: Updated.

报告人：周宇红

单位：复旦大学附属中山医院

摘要号: 11572

标题：Efficacy of eribulin administered in combination with an immune checkpoint inhibitor (ICI) and anlotinib as salvage treatment for patients (pts) with advanced adult soft tissue sarcoma (STS).

报告人：郭曦

单位：复旦大学附属中山医院

备注：排名不分先后，按照摘要号进行

如有遗漏或任何问题，请给我们留言~